Beneficial Effects of (pGlu-Gln)-CCK-8 on Energy Intake and Metabolism in High Fat Fed Mice are Associated with Alterations of Hypothalamic Gene Expression

Abstract

Cholecystokinin (CCK) is a gastrointestinal hormone with potential therapeutic promise for obesity-diabetes. The present study examined the effects of twice daily administration of the N-terminally modified stable CCK-8 analogue, (pGlu-Gln)-CCK-8, on metabolic control and hypothalamic gene expression in high fat fed mice. Sub-chronic twice daily injection of (pGlu-Gln)-CCK-8 for 16 days significantly decreased body weight (p<0.05), energy intake (p<0.01), circulating blood glucose (p<0.001), and plasma insulin (p<0.001) compared to high fat controls. Furthermore, (pGlu-Gln)-CCK-8 markedly improved glucose tolerance (p<0.05) and insulin sensitivity (p<0.05). Assessment of hypothalamic gene expression on day 16 revealed significantly elevated NPY (p<0.05) and reduced POMC (p<0.05) and MC4R (p<0.05) mRNA expression in (pGlu-Gln)-CCK-8 treated mice. High fat feeding or (pGlu-Gln)-CCK-8 treatment had no significant effects on hypothalamic gene expression of receptors for leptin, CCK, and GLP-1. These studies underscore the potential of (pGlu-Gln)-CCK-8 for the treatment of obesity-diabetes and suggest modulation of NPY and melanocortin related pathways may be involved in the observed beneficial effects.

Introduction

Cholecystokinin (CCK), a gut peptide secreted by endocrine I-cells in response to feeding, regulates short-term energy balance through stimulation of central satiety [1]. CCK exerts this effect through binding to specific CCK\_Rs on vagal afferent neurons, activating central pathways involved in energy regulation [1]. Vagal afferents are essential to CCK-induced satiety, as demonstrated through studies displaying an increase in vagal afferent discharge after peripheral CCK injection, or reduction in satiety following surgical destruction of peripheral vagal terminals [2]. Notably, these vagal afferents innervate neurons on the nucleus of the tractus solitaries (NTS) that terminate in the hypothalamus [1]. Accumulating evidence suggests that sustained CCK\_R activation is a potential therapeutic option for obesity and related metabolic disease. Thus, we have recently developed the potent and stable CCK\_R agonist, (pGlu-Gln)-CCK-8, an enzymatically stable CCK-8 analogue, with a significantly prolonged biological half-life [3]. We have shown that (pGlu-Gln)-CCK-8 causes sustained weight loss and improves both insulin resistance and glucose tolerance in mouse models of obesity-diabetes [3,4]. Despite the therapeutic potential for (pGlu-Gln)-CCK-8, there is a lack of information on its central effects. Therefore, the current study examined the consequence of twice daily (pGlu-Gln)-CCK-8 administration on metabolic status and the expression of key hypothalamic genes involved in energy balance in high fat mice.

Materials and Methods

Peptides

(pGlu-Gln)-CCK-8 was obtained from American peptide company (Sunnyvale, USA) and characterized as described previously [3].

Animals

Male Swiss NIH mice (Harlan UK Ltd.; 10–12 weeks) had free access to drinking water and standard rodent maintenance (10% fat, 30% protein and 60% carbohydrate, Trouw Nutrition, Cheshire, UK) or high fat (45% fat, 35% carbohydrate and 20% protein, Special Diet Services, UK)
diet as appropriate. Prior to commencement of studies, high-fat mice were maintained on high fat diet from 6 weeks of age for 140 days. All animal experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986. The animals were housed individually in an air-conditioned room with a 12-h light/12-h darkness cycle.

In vivo studies

Over a 16-day period, high fat mice on a reversed light cycle (lights off between 09:30–21:30 h) received twice daily i.p. injections (09:00 and 17:00 h) of either saline vehicle (0.9% (w/v), NaCl) or (pGlu-Gln)-CCK-8 (25 nmol/kg body wt). Body weight, total accumulated food intake, nonfasting plasma glucose and insulin concentrations were recorded on day 16. In addition, at the end of the study, i.p. glucose tolerance (18 mmol/kg body wt) and insulin sensitivity (20U/kg body wt) were measured in mice treated with saline vehicle (0.9% (w/v), NaCl) or (pGlu-Gln)-CCK-8 (25 nmol/kg body wt).

Gene expression

On day 16, hypothalamic tissue (n = 6) was excised and immediately snap-frozen in liquid nitrogen and stored at −80°C before RNA extraction for gene expression analysis. Briefly, total RNA was isolated and purified using QIAzol lysis reagent (Qiagen, West Sussex, UK) and RNA concentration determined from the absorbance at 260 nm. First-strand cDNA was synthesized using an oligo dT(12–18) primer, 10 mM dNTP and 200 U Superscript II reverse transcriptase (Invitrogen, Paisley, UK) in a final volume of 20 μl using a GeneStorm GS1 Thermal Cycler (Gene Technologies Ltd, Essex, UK). Genes were amplified using specific primers for Neuropeptide Y (NPY), proopiomelanocortin (POMC), melanocortin receptor 4 (MC4R), leptinR, CCK1R, glucagon-like peptide-1 (GLP-1)R and β-actin (Atcb). The DNA-denaturing step was carried out at 95°C for 5 min in a Roche LightCycler 1.5 carousel-based thermal cycler (Roche Diagnostics, West Sussex, UK). CDNA amplification then commenced for 40 cycles with 95°C denaturation for 30s, 58°C annealing for 30s, and 72°C elongation for 30s with SYBR green fluorescence being read after each cycle and recorded by Roche LightCycler Software (Version 3.5) to construct an amplification curve. Gene expression was calculated from 2^ΔCt values normalized to mouse Atcb control primer. Age-matched lean control NIH male mice maintained on standard rodent maintenance diet were used for comparative purposes.

Table 1 Effects of (pGlu-Gln)-CCK-8 on metabolic parameters in high fat fed mice.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>High fat</th>
<th>(pGlu-Gln)-CCK-8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accumulated food intake (kJ)</td>
<td>1710.5 ± 19.4</td>
<td>1497.3 ± 45.3*</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td>50.3 ± 1.6</td>
<td>43.3 ± 1.3**</td>
</tr>
<tr>
<td>Nonfasting glucose (mM)</td>
<td>25.9 ± 2.0</td>
<td>15.1 ± 1.1***</td>
</tr>
<tr>
<td>Nonfasting insulin (pM)</td>
<td>1684.3 ± 130.4</td>
<td>494.6 ± 109.1***</td>
</tr>
<tr>
<td>Glucose tolerance: 0–60 min glucose AUC (mM-min)</td>
<td>498.5 ± 70.4</td>
<td>313.4 ± 31.1**</td>
</tr>
<tr>
<td>Insulin sensitivity: glucose 0–60 min AUC (mM-min)</td>
<td>83.1 ± 6.1</td>
<td>108.2 ± 7.9*</td>
</tr>
</tbody>
</table>

Parameters were measured after 16 days twice daily treatment with saline or (pGlu-Gln)-CCK-8 (25 nmol/kg body wt). For glucose tolerance, glucose (18 mmol/kg body wt) was administered in nonfasted mice and 0–60 min plasma glucose AUC values calculated. For insulin sensitivity, insulin (20U/kg body wt) was administered in nonfasted mice and 0–60 min AUC values calculated. Values are mean ± SEM for 6 mice. *p < 0.05, **p < 0.01, and ***p < 0.001 compared to high fat group.

Results

Effects of (pGlu-Gln)-CCK-8 on metabolic control in high fat fed mice

Twice daily treatment with (pGlu-Gln)-CCK-8 resulted in significantly (p < 0.05) decreased accumulated food intake by day 16 compared to high fat controls. Body weights of (pGlu-Gln)-CCK-8 mice were significantly (p < 0.01) decreased, together with reductions (p < 0.001) of circulating glucose and insulin (Table 1). AUC glucose values were significantly (p < 0.05) lowered following i.p. glucose, and the hypoglycemic action of insulin was significantly (p < 0.05) augmented, in (pGlu-Gln)-CCK-8 treated mice compared to high fat controls (Table 1).

Effects of (pGlu-Gln)-CCK-8 on hypothalamic gene expression in high fat fed mice

NPY expression was significantly (p < 0.05) enhanced in (pGlu-Gln)-CCK-8-treated mice compared to high fat and lean control mice (Fig. 1a). In addition, there was a significant decrease (p < 0.05) in mRNA expression of POMC and MC4R in (pGlu-Gln)-CCK-8 mice compared to high fat controls (Fig. 1b, c). Moreover, MC4R expression was returned to levels comparable with lean control mice (Fig. 1c). There were no significant differences in hypothalamic mRNA expression of leptinR, CCK1R, or GLP-1R between any of the groups (Fig. 1d–f).

Discussion

In harmony with previous observations [3, 4], twice daily administration of (pGlu-Gln)-CCK-8 to high fat fed mice resulted in a marked improvement in glucose homeostasis and insulin sensitivity. Decreased accumulated energy intake was also observed in the current study, together with substantially reduced body weight and circulating glucose and insulin. We have already shown that these beneficial effects are not reproduced by simple dietary restriction, or associated with changes in energy expenditure [3]. Therefore, in this study we examined the impact of (pGlu-Gln)-CCK-8 treatment on the expression of key hypothalamic genes involved in energy balance, in an attempt to elucidate possible underlying mechanisms.

Treatment with (pGlu-Gln)-CCK-8 for 16 days in high fat fed mice resulted in an unexpected increase in NPY gene expression compared to both lean control and saline treated high fat mice. As such, increased NPY activity is generally associated with elevated food intake. Thus, normal rats receiving hypothalamic injections of an NPY expression vector display a 2-fold increase in NPY mRNA expression and develop significantly increased energy intake leading to obesity [5]. However, in agreement with the current study, hypothalamic NPY mRNA expression is decreased in CCK1R knockout rats [6]. This suggests that modulation of hypothalamic NPY signaling may play a role in CCK-mediated effects on energy intake. A functional interaction between CCK1R signaling and NPY has been proposed through experiments revealing co-localization of CCK1R and NPY immunoreactivity in the hypothalamus [6]. However, we observed no
significant change in CCK1R gene expression in the current study, although there was a tendency towards increased CCK1R expression, which may have reached significance with a larger sample number.

POMC neurons in the NTS are activated by CCK and this effect is blocked by CCK antagonists [7]. This CCK/POMC effect is thought to be dependent on MC4R signaling pathways in the hypothalamus [8]. Indeed, MC4R knockout mice have delayed meal termination and reduced sensitivity to CCK [8]. Moreover, the melanocortin MC4R antagonist, SHU9119, prevents CCK-induced suppression of feeding [7]. Interestingly, POMC mRNA expression is increased in CCK1R knockout rats [6]. Thus, melanocortin signaling pathways appear to be fundamental for the satiety effect of CCK. In agreement, the present study has shown significant decreases in the hypothalamic expression of both POMC and MC4R in response to twice daily intraperitoneal injection with (pGlu-Gln)-CCK-8. We also assessed the effect of (pGlu-Gln)-CCK-8 treatment on the expression of receptors for leptin and GLP-1, since both compounds have well characterized effects on energy homeostasis and are known to interact with CCK [9,10]. However, there were no changes in hypothalamic gene expression of either receptor in the current study.

In conclusion, the present study indicates that the therapeutic efficacy of (pGlu-Gln)-CCK-8 is associated with modulation of NPY, POMC, and MC4R gene expression in the hypothalamus. However, further studies are required to fully delineate the mechanism of action of these effects and the potential of stable analogues of CCK-8 as novel therapeutic agents for obesity-diabetes.

Acknowledgements

These studies were supported by the SAAD Trading and Contracting Company and the Department of Education and Learning, Northern Ireland.

Conflict of Interest

N.I. and P.R.F. hold shares with Diabetica Ltd, which has patents for exploitation of peptide therapeutics.

References

1. Rethfeld JF. Acta Physiol (Oxf) 2011; 201: 405–411
7. Millington GW. Nutr Metab (Lond) 2007; 4: 18